Hangzhou Tigermed Consulting (03347) released its annual performance, with a net profit attributable to the parent company of 888 million yuan, a year-on-year increase of 119.15%.

Hangzhou Tigermed Consulting (03347) announced its annual performance for the year ending December 31, 2025. The group achieved operating income of 6.833 billion yuan, a year-on-year increase of 3.48%; net profit attributable to the listed company was 888 million yuan, a year-on-year increase of 119.15%; basic earnings per share were 1.04 yuan, with a proposed cash dividend of 1.26 yuan per 10 shares to all shareholders. The announcement stated that the revenue of the Clinical Trial Technology Services department was 3.267 billion yuan, compared to 3.178 billion yuan in the same period. The revenue of the Clinical Trial Related Services and Laboratory Services department increased by 4.1% from 3.425 billion yuan in the same period to 3.566 billion yuan.